Cassava Sciences stock up on Alzheimer’s update (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences (SAVA) stock gains as company completes Phase 3 trial for Alzheimer's candidate simufilam, to release topline data by end of 2024. Read more here.
Search Group
Share To
Comments
About Screade
Screade® Inc. version 1.0, copyright 2016 - 2024
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments